Julia Y S Tsang1, Wai-Ling Au1, Kwan-Yin Lo1, Yun-Bi Ni1, Thazin Hlaing2, Jintao Hu3, Siu-Ki Chan4, Kui-Fat Chan5, Sai-Yin Cheung5, Gary M Tse6. 1. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong. 2. Department of Anatomic Pathology, Centro Hospitalar Conde de Sao Januario, Macao SAR, China. 3. Department of Pathology, Shenzhen People's Hospital, Shenzhen, 518020, China. 4. Department of Pathology, Kwong Wah Hospital, Yau Ma Tei, Hong Kong. 5. Department of Pathology, Tuen Mun Hospital, Tuen Mun, Hong Kong. 6. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong. garytse@cuhk.edu.hk.
Abstract
PURPOSE: Clinical trials showing programmed death (PD)-1-PD-ligand 1 (L1) axis as a promising therapeutic target in melanoma and non-small cell lung cancers have made the pathway a focus of recent attention. However, the data regarding PD-L1/PD-1 in breast cancer are inconsistent. Given the heterogeneity of breast cancers, the clinical relevance of PD-L1 and PD-1 tumor infiltrating lymphocytes (TIL) may vary according to subtypes of breast cancer. We aim to investigate PD-L1 expression in a large cohort of breast cancers and analyze its clinico-pathological as well as outcome relationship according to molecular subtypes. Also, we evaluate the relationship of PD-1 TIL and PD-L1 expression with patients' survival, particularly for breast cancers with high TIL. METHODS AND RESULTS: Immunohistochemical analysis of PD-L1 on tissue arrays for 1091 breast cancer patients and PD-1 TIL on 97 whole sections was performed. Associations of PD-L1 with luminal cancers (p < 0.001) and features associated with that subtype [lower histologic grade, absence of necrosis, ER, PR, and AR expression (p < 0.001)] were observed. However, in HER2+ breast cancers, PD-L1 was an independent poor prognostic indicator (DFS: HR = 1.866, p = 0.001; OS: HR = 1.517, p = 0.036). Interestingly, HER2+ cancers showed a lower PD-1 TIL level compared to the other high TIL cases (p = 0.011). Cases with low PD-TIL but high PD-L1 expression showed the worst survival. This could be indicative of an active immune suppression by PD-L1 expression. CONCLUSIONS: Our data showed the relevance of PD-L1 expression in HER2+ breast cancer. A combined evaluation of PD-L1 and PD-1 TIL in the prognosis of breast cancer might also be of value in treatment prediction.
PURPOSE: Clinical trials showing programmed death (PD)-1-PD-ligand 1 (L1) axis as a promising therapeutic target in melanoma and non-small cell lung cancers have made the pathway a focus of recent attention. However, the data regarding PD-L1/PD-1 in breast cancer are inconsistent. Given the heterogeneity of breast cancers, the clinical relevance of PD-L1 and PD-1 tumor infiltrating lymphocytes (TIL) may vary according to subtypes of breast cancer. We aim to investigate PD-L1 expression in a large cohort of breast cancers and analyze its clinico-pathological as well as outcome relationship according to molecular subtypes. Also, we evaluate the relationship of PD-1 TIL and PD-L1 expression with patients' survival, particularly for breast cancers with high TIL. METHODS AND RESULTS: Immunohistochemical analysis of PD-L1 on tissue arrays for 1091 breast cancerpatients and PD-1 TIL on 97 whole sections was performed. Associations of PD-L1 with luminal cancers (p < 0.001) and features associated with that subtype [lower histologic grade, absence of necrosis, ER, PR, and AR expression (p < 0.001)] were observed. However, in HER2+ breast cancers, PD-L1 was an independent poor prognostic indicator (DFS: HR = 1.866, p = 0.001; OS: HR = 1.517, p = 0.036). Interestingly, HER2+ cancers showed a lower PD-1 TIL level compared to the other high TIL cases (p = 0.011). Cases with low PD-TIL but high PD-L1 expression showed the worst survival. This could be indicative of an active immune suppression by PD-L1 expression. CONCLUSIONS: Our data showed the relevance of PD-L1 expression in HER2+ breast cancer. A combined evaluation of PD-L1 and PD-1 TIL in the prognosis of breast cancer might also be of value in treatment prediction.
Entities:
Keywords:
Breast cancer subtype; Human epidermal growth factor receptor 2; Immunohistochemistry; Programmed death ligand 1; Tumor infiltrating lymphocyte
Authors: Deepak Mittal; Dipti Vijayan; Joost Neijssen; Joost Kreijtz; Maurice M J M Habraken; Hans Van Eenennaam; Andrea Van Elsas; Mark J Smyth Journal: Oncoimmunology Date: 2019-08-26 Impact factor: 8.110
Authors: Marcelo Sobral-Leite; Koen Van de Vijver; Magali Michaut; Rianne van der Linden; Gerrit K J Hooijer; Hugo M Horlings; Tesa M Severson; Anna Marie Mulligan; Nayana Weerasooriya; Joyce Sanders; Annuska M Glas; Diederik Wehkamp; Lorenza Mittempergher; Kelly Kersten; Ashley Cimino-Mathews; Dennis Peters; Erik Hooijberg; Annegien Broeks; Marc J van de Vijver; Rene Bernards; Irene L Andrulis; Marleen Kok; Karin E de Visser; Marjanka K Schmidt Journal: Oncoimmunology Date: 2018-09-11 Impact factor: 8.110
Authors: Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir Journal: Mol Diagn Ther Date: 2022-02-01 Impact factor: 4.074
Authors: Cinzia Solinas; Soizic Garaud; Pushpamali De Silva; Anaïs Boisson; Gert Van den Eynden; Alexandre de Wind; Paolo Risso; Joel Rodrigues Vitória; François Richard; Edoardo Migliori; Grégory Noël; Hugues Duvillier; Ligia Craciun; Isabelle Veys; Ahmad Awada; Vincent Detours; Denis Larsimont; Martine Piccart-Gebhart; Karen Willard-Gallo Journal: Front Immunol Date: 2017-10-30 Impact factor: 7.561